Insider Buying: GSK (LON:GSK) Insider Acquires 637 Shares

GSK plc (LON:GSK) insider Anne Beal bought 637 shares of GSK stock in a transaction dated Friday, September 18th. The stock was acquired at an average price of GBX 4,985 per share, with a total value of £31,754.45.

GSK Price Performance

Shares of GSK stock traded down GBX 5 during trading hours on Tuesday, reaching GBX 1,906. The company had a trading volume of 5,121,120 shares, compared to its average volume of 13,080,331. The company has a debt-to-equity ratio of 103.36, a quick ratio of 0.73 and a current ratio of 0.82. The stock has a fifty day moving average of GBX 1,889.93 and a 200-day moving average of GBX 1,951.92. The company has a market capitalization of £76.37 billion, a price-to-earnings ratio of 16.18, a PEG ratio of 1.24 and a beta of 0.29. GSK plc has a 12-month low of GBX 1,455 and a 12-month high of GBX 2,282.

GSK (LON:GSK) last announced its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a return on equity of 28.35% and a net margin of 14.52%. On average, equities analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Analysts Set New Price Targets

GSK has been the subject of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 price objective on shares of GSK in a report on Wednesday, July 29th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a GBX 1,975 target price on shares of GSK in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a report on Tuesday, September 15th. Finally, Berenberg Bank increased their price target on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a “hold” rating in a research note on Tuesday, September 15th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, GSK presently has an average rating of “Hold” and a consensus target price of GBX 2,064.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.